Ultragenyx Pharma (RARE) PT Raised to $75 at Cowen

Cowen analyst Yaron Werber raised the price target on Ultragenyx Pharma (NASDAQ: RARE) to $75.00 (from $59.00) while maintaining a Outperform rating.

The analyst commented, "We are making updates to our model to reflect preannounced Q4 results, FY20 financial guidance, and are now adding revenues for DTX301 & DTX401. Our new PT of $75 (+$16) is based on 35x (unchanged) $2.85E (+$0.98) ‘24 EPS discounted by 10% (unchanged)."

You May Also Be Interested In

• Shoe Station Group (SHOE) PT Lowered to $15 at Williams Trading
• Ametek Inc. (AME) PT Raised to $290 at BNP Paribas Exane
• HubSpot Inc (HUBS) PT Raised to $225 at Stifel Ahead of UNBOUND Conference